Previous 10 | Next 10 |
2024-07-08 10:00:00 ET Pfizer (NYSE: PFE) may not be the must-have pharmaceutical investment it was at one point. If your priority is reliable divided income, however, the drugmaker remains a rock-solid pick. Not only has it paid a dividend like clockwork for decades, the company ha...
2024-07-08 05:21:00 ET The past few years have been tough ones for investors holding shares of Pfizer (NYSE: PFE) . The Big Pharma stock is down by more than half from the peak it set in late 2021. Pfizer's stock price was hammered, but that didn't prevent the company from meeti...
2024-07-06 05:07:00 ET The benchmark S&P 500 index keeps breaking new records thanks in large part to a handful of stocks at the top. Luckily for income-seeking investors, there are some highly reliable dividend stocks out there that haven't been swept up in the excitement. Shar...
2024-07-05 15:04:46 ET More on Novo Nordisk Novo Nordisk: Buy On Dips Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk’s Ozempic, Wegovy linked to eye diso...
2024-07-05 13:04:53 ET More on Nio, Pfizer. NIO: It's Getting Interesting NIO Stock: Slam The Brakes On This No-Moat EV Operator Pfizer: It Could Be A Bargain Chinese EV makers slapped with 'countervailing' EU tariffs Biggest stock movers today: Crypt...
2024-07-05 09:18:15 ET More on Pfizer Pfizer: It Could Be A Bargain Wall Street Lunch: Pfizer Looks To Take Next Step In Weight-Loss Drugs Pfizer: Seriously Undervalued At Peak Pessimism COVID infections could be seeing a summer surge based on CDC data ...
2024-07-05 05:29:10 ET Summary Arbutus Biopharma's three-pronged strategy targets cHBV by suppressing HBV DNA, reducing viral antigens, and boosting immune response. Imdusiran (AB-729) shows promise in Phase 2 trials, potentially leading to a functional cure for chronic hepatitis ...
2024-07-04 12:45:03 ET Summary Novo Nordisk's Ozempic continues gaining popularity in weight management and diabetes markets, along with Wegovy, raising the question of whether the same can be hoped for the stock. There's a lot to like about the company. It's seeing robust sales g...
2024-07-04 11:30:00 ET Summary This article will present an in-depth analysis of drugs being developed to combat obesity and related diseases. Pharmaceutical companies are highly interested in the global obesity treatment market, which is expected to exceed $100 billion by 2030. ...
2024-07-04 09:00:00 ET Summary First half of 2024 is profitable for investors, S&P 500 up 14.48% and Dividend Harvesting Portfolio ROI at 14.05%. Market outlook positive with Fed rate cuts expected, unemployment increase may signal recession. Portfolio generates $1,552.82 ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
2024-07-20 10:00:00 ET On July 11, Pfizer (NYSE: PFE) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage weight loss programs into mid-stage trials. In due time, the mo...
2024-07-18 13:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...